scholarly journals Adult B‐ and T‐lymphoblastic lymphoma treated with a paediatric acute lymphoblastic leukaemia regimen have excellent outcomes—a short report from two Sydney centres

2020 ◽  
Vol 191 (2) ◽  
Author(s):  
Richard Blennerhassett ◽  
John Kwan ◽  
Luke Coyle ◽  
Kelly Wong ◽  
Matthew Greenwood
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Lymphoblastic Lymphoma ◽  
Short Report ◽  
T Lymphoblastic Lymphoma

Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?

2007 ◽  
Vol 48 (9) ◽  
pp. 1745-1754 ◽  
Author(s):  
Anne Uyttebroeck ◽  
Vera Vanhentenrijk ◽  
Anne Hagemeijer ◽  
Nancy Boeckx ◽  
Marleen Renard ◽  
...  
Keyword(s):  
T Cell ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Lymphoblastic Lymphoma

scholarly journals Sinonasal Lymphoma Presenting as a Probable Sanctuary Site for Relapsed B Acute Lymphoblastic Leukaemia: A Case Report and Review of the Literature

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
W. Y. Lim ◽  
R. Care ◽  
M. Lau ◽  
S. Chiruka ◽  
P. J. D. Dawes
Keyword(s):  
Case Report ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Nasal Septum ◽  
Poor Prognosis ◽  
Lymphoblastic Lymphoma ◽  
Late Relapse ◽  
Review Of The Literature ◽  
Unique Case ◽  
Non Hodgkin Lymphoma

Sinonasal lymphoma is a non-Hodgkin lymphoma (NHL) representing 1.5% of all lymphomas. It presents as an unremitting ulceration with progressive destruction of midline sinonasal and surrounding structures. Poor prognosis warrants early treatment although diagnosis is challenging and frequently delayed. It is usually primary in origin and to our knowledge the sinonasal region has never been reported as a sanctuary site in leukaemia/lymphoma relapse. We present a unique case of B-cell ALL (acute lymphoblastic leukaemia) with late relapse to the nasal septum as a sinonasal lymphoblastic lymphoma and with genetic support for this as a sanctuary site.

scholarly journals British OsteoNEcrosis Study (BONES) protocol: a prospective cohort study to examine the natural history of osteonecrosis in older children, teenagers and young adults with acute lymphoblastic leukaemia and lymphoblastic lymphoma

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e027204
Author(s):  
Nadia Amin ◽  
Sally Kinsey ◽  
Richard Feltbower ◽  
Jeannette Kraft ◽  
Elizabeth Whitehead ◽  
...  
Keyword(s):  
Cohort Study ◽  
Natural History ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Lymphoblastic Lymphoma ◽  
Vertebral Fracture Assessment ◽  
Time Points ◽  
History Of ◽  
The Uk ◽  
Prospective Longitudinal

IntroductionOsteonecrosis is a well-recognised treatment-related morbidity risk in patients diagnosed with acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL), with a high rate of affected patients requiring surgical intervention. Patients may have asymptomatic changes on imaging studies that spontaneously regress, and little is known about the natural history of osteonecrotic changes seen. The main aim of the British OsteoNEcrosis Study (BONES) is to determine the incidence of symptomatic and asymptomatic osteonecrosis in the lower extremities of survivors of ALL or LBL diagnosed aged 10–24 years in the UK at different time points in their treatment. This study also aims to identify risk factors for progression and the development of symptomatic osteonecrosis in this population, as well as specific radiological features that predict for progression or regression in those with asymptomatic osteonecrosisMethods and analysisBONES is a prospective, longitudinal cohort study based at principal treatment centres around the UK. Participants are patients aged 10–24 years diagnosed with ALL or LBL under standard criteria. Assessment for osteonecrosis will be within 4 weeks of diagnosis, at the end of delayed intensification and 1, 2 and 3 years after the start of maintenance therapy. Assessment will consist of MRI scans of the lower limbs and physiotherapy assessment. Clinical and biochemical data will be collected at each of the time points. Bone mineral density data and vertebral fracture assessment using dual-energy X-ray absorptiometry will be collected at diagnosis and annually for 3 years after diagnosis of malignancy.Ethics and disseminationEthical approval has been obtained through the Yorkshire and Humber Sheffield Research Ethics Committee (reference number: 16/YH/0206). Study results will be published on the study website, in peer-reviewed journals and presented at relevant conferences and via social media.Trial registration numberNCT02598401; Pre-results.

Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation

2018 ◽  
Vol 72 (3) ◽  
pp. 251-257 ◽  
Author(s):  
Prajwal Boddu ◽  
Beenu Thakral ◽  
Ahmed Alhuraiji ◽  
Naveen Pemmaraju ◽  
Tapan Kadia ◽  
...  
Keyword(s):  
Lymphoblastic Leukaemia ◽  
Lymphoblastic Lymphoma ◽  
Accurate Diagnosis ◽  
Detailed Report ◽  
Mediastinal Neoplasms ◽  
Molecular Approaches ◽  
Clinical Presentations ◽  
Diagnostic Approaches ◽  
T Lymphoblastic Lymphoma ◽  
Case Based

T-lymphoblastic lymphoma and thymoma are distinct primary mediastinal neoplasms that can have similar clinical presentations and overlapping histological features. Microscopic distinction is occasionally difficult because the immature lymphocytes associated with thymoma may resemble T-lymphoblastic leukaemia/lymphoma cells, morphologically and immunohistochemically. An accurate diagnosis assumes particular importance since the treatment approaches for these two entities differ considerably. Multimodality diagnostic approaches incorporating histological, flow cytometry immunophenotypic‚ and molecular approaches are required. In this article, we describe four patients, each presenting with a mediastinal tumour in different clinicopathological settings. A detailed report of each case will follow, illustrating the challenges involved in the diagnosis in patients with these mediastinal neoplasms.

Sign in / Sign up

Export Citation Format

Share Document